Cristin-resultat-ID: 1760534
Sist endret: 20. februar 2020, 16:11
NVI-rapporteringsår: 2019
Resultat
Vitenskapelig artikkel
2019

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Bidragsytere:
  • Johanna Elin Gehin
  • Guro Løvik Goll
  • David John Warren
  • Silje Watterdal Syversen
  • Joseph Sexton
  • Eldri Kveine Strand
  • mfl.

Tidsskrift

Arthritis Research & Therapy
ISSN 1478-6354
e-ISSN 1478-6362
NVI-nivå 2

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2019
Publisert online: 2019
Volum: 21
Sider: 1 - 10
Artikkelnummer: 256
Open Access

Importkilder

Scopus-ID: 2-s2.0-85075793784

Beskrivelse Beskrivelse

Tittel

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Sammendrag

Objectives To identify a therapeutic target interval for certolizumab pegol drug levels and examine the influence of anti-drug antibodies in patients with inflammatory joint diseases. Methods Certolizumab pegol and anti-drug antibody levels were measured in serum samples collected after 3 months of certolizumab pegol treatment in 268 patients with inflammatory joint diseases (116 axial spondyloarthritis, 91 rheumatoid arthritis and 61 psoriatic arthritis) in the NOR-DMARD study. Treatment response was defined by Ankylosing Spondylitis Disease Activity Score Clinically important improvement in axial spondyloarthritis, European League Against Rheumatism good/moderate response in rheumatoid arthritis, and improvement in 28-joint Disease Activity Score of ≥ 0.6 in PsA. Serum drug levels and anti-drug antibodies were analysed using automated in-house assays. Results Certolizumab pegol serum levels varied considerably between individuals (median (IQR) 32.9 (17.3–43.9) mg/L). Certolizumab pegol level ≥ 20 mg/L was associated with treatment response for the total inflammatory joint disease population, with odds ratio (OR) 2.3 (95% CI 1.2–4.5, P = 0.01) and OR 1.9 (95% CI 1.0–3.5, P = 0.05) after 3 and 6 months of treatment, respectively. For individual diagnoses, this association was most consistent for axial spondyloarthritis, with OR 3.4 (95% CI 1.0–11.1, P  40 mg/L was not associated with any additional benefit for any of the diagnoses. Anti-drug antibodies were detected in 6.1% (19/310) of samples and were associated with low certolizumab pegol levels (P 

Bidragsytere

Johanna Gehin

Bidragsyterens navn vises på dette resultatet som Johanna Elin Gehin
  • Tilknyttet:
    Forfatter
    ved Avdeling for medisinsk biokjemi ved Universitetet i Oslo
  • Tilknyttet:
    Forfatter
    ved Avdeling for medisinsk biokjemi ved Oslo universitetssykehus HF

Guro Løvik Goll

  • Tilknyttet:
    Forfatter
    ved Klinikk for revmatologi poliklinikk og forskning ved Diakonhjemmet sykehus

David John Warren

  • Tilknyttet:
    Forfatter
    ved Avdeling for medisinsk biokjemi ved Oslo universitetssykehus HF

Silje Watterdal Syversen

  • Tilknyttet:
    Forfatter
    ved Klinikk for revmatologi poliklinikk og forskning ved Diakonhjemmet sykehus

Joseph Sexton

  • Tilknyttet:
    Forfatter
    ved Klinikk for revmatologi poliklinikk og forskning ved Diakonhjemmet sykehus
1 - 5 av 9 | Neste | Siste »